Figure 2.

Silencing of MIR106A-5p inhibits NPC proliferation and migration in vivo. (A) Visualization of lung metastasis after intravenous injection of CNE-2 cells, with or without knockdown of MIR106A-5p, in BALB/c mice. Representative images of bioluminescence signals and normalized photon flux are shown. (B) Graph representing mean intensity of fluorescence 7 weeks after tumor injection (*P < 0.05, t-test). (C) CNE2 cells transfected with MIR106A-5p inhibitor and labeled with DiI were injected into the perivitelline space of zebrafish embryos. Migration of CNE2 cells was measured using fluorescence microscopy at day 8 post-injection. (D) Quantification of migratory cell numbers and analysis using Student’s t-test (**P < 0.01). (E) Cells with stable silencing of MIR106A-5p or control cells were subcutaneously transplanted in nude mice (n = 3 per group). Subcutaneous tumor volumes at day 21 are shown (*P < 0.05, t-test). (F) Immunohistochemistry (IHC) analysis of tumor MAP1LC3B and MKI67 expression across tumor groups. Scale bar: 50 μm. Quantification of IHC staining for MAP1LC3B and MKI67 expression using Student’s t-test (***P < 0.001) (G) and Pearson correlation between MAP1LC3B and MKI67 expression (H). Linear regression. All experiments were repeated three times. Data represent mean ± SEM